Sarcoidosis-like reaction secondary to adalimumab treatment in a patient with axial spondyloarthritis
Abstract
Anti-TNF agents, namely adalimumab, are safe drugs that represent an important arsenal in the treatment of immune-mediated inflammatory diseases. “Paradoxical effects” have been described with their use. A sarcoidosis “like” reaction induced by these agents is rare and is characterized by a systemic granulomatous reaction indistinguishable from sarcoidosis. We present a 55-year-old male patient, with axial spondyloarthritis, treated with with adalimumab. About 17 months under this therapy, he complained of dry cough and wheezing. Chest CT showed a peri-lymphatic and pericisural micronodular pattern and hilo-mediastinal lymph nodes, suggestive of sarcoidosis. Angiotensin converting enzyme was increased. Assuming the hypothesis of a sarcoidosis-like reaction secondary to adalimumab this therapy was discontinued with progressive improvement in the patient's complaints and in the radiological changes.
Keywords
References
- Bradley J. TNF-mediated inflammatory disease. J Pathol 2008;214:149–60. DOI: https://doi.org/10.1002/path.2287
- Wendling D, Prati C. Paradoxical effects of anti-TNF-α agents in inflammatory diseases. Expert Rev Clin Immunol. 2014;10:159–69. DOI: https://doi.org/10.1586/1744666X.2014.866038
- Bhargava S, Perlman DM, Allen TL, et al. Adalimumab induced pulmonary sarcoid reaction. Respir Med Case Rep 2013;10:53-5. DOI: https://doi.org/10.1016/j.rmcr.2013.07.002
- EMA Europe [Internet]. Humira product information. [cited 2022 Apr 20]. Available from: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf
- Obi ON, Lower EE, Baughman RP. Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. Expert Rev Clin Pharmacol 2021;14:179–210. DOI: https://doi.org/10.1080/17512433.2021.1878024
- Chopra A, Nautiyal A, Kalkanis A, Judson MA. Drug-induced sarcoidosis-like reactions. Chest 2018;154:664–77. DOI: https://doi.org/10.1016/j.chest.2018.03.056
- Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361:1111-8. DOI: https://doi.org/10.1016/S0140-6736(03)12888-7
- Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153-65. DOI: https://doi.org/10.1056/NEJMra071714
- Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011;41:256–64. DOI: https://doi.org/10.1016/j.semarthrit.2010.11.002
- Decock A, Van Assche G, Vermeire S, et al. Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy? J Crohns Colitis 2017;11:378-83. DOI: https://doi.org/10.1093/ecco-jcc/jjw155
- Khasnis AA, Calabrese LH. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum 2010;40:147-63. DOI: https://doi.org/10.1016/j.semarthrit.2009.09.001
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2022 The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.